FY2017 EPS Estimates for Paratek Pharmaceuticals, Inc. (PRTK) Raised by Analyst

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) – Leerink Swann lifted their FY2017 earnings per share estimates for shares of Paratek Pharmaceuticals in a research report issued to clients and investors on Wednesday. Leerink Swann analyst P. Matteis now forecasts that the specialty pharmaceutical company will post earnings of ($3.42) per share for the year, up from their prior estimate of ($3.65). Leerink Swann also issued estimates for Paratek Pharmaceuticals’ Q4 2017 earnings at ($0.88) EPS, Q1 2018 earnings at ($0.95) EPS, Q2 2018 earnings at ($1.02) EPS, Q3 2018 earnings at ($1.26) EPS, Q4 2018 earnings at ($1.19) EPS, FY2018 earnings at ($4.43) EPS and FY2019 earnings at ($3.71) EPS.

Other research analysts also recently issued research reports about the company. BidaskClub raised Paratek Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $50.00 price objective on shares of Paratek Pharmaceuticals in a report on Wednesday, August 23rd. HC Wainwright upped their price objective on Paratek Pharmaceuticals from $36.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, July 18th. Zacks Investment Research raised Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research note on Saturday, August 5th. Finally, Guggenheim began coverage on Paratek Pharmaceuticals in a research note on Tuesday, October 24th. They issued a “buy” rating and a $44.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $40.00.

ILLEGAL ACTIVITY WARNING: “FY2017 EPS Estimates for Paratek Pharmaceuticals, Inc. (PRTK) Raised by Analyst” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://ledgergazette.com/2017/11/13/fy2017-eps-estimates-for-paratek-pharmaceuticals-inc-prtk-raised-by-analyst.html.

Paratek Pharmaceuticals (NASDAQ:PRTK) opened at $21.65 on Monday. Paratek Pharmaceuticals has a 1-year low of $12.45 and a 1-year high of $29.00. The company has a quick ratio of 11.88, a current ratio of 10.53 and a debt-to-equity ratio of 0.49.

Several hedge funds have recently bought and sold shares of PRTK. Great West Life Assurance Co. Can acquired a new position in shares of Paratek Pharmaceuticals in the 3rd quarter valued at $104,000. SG Americas Securities LLC acquired a new position in shares of Paratek Pharmaceuticals in the 3rd quarter valued at $123,000. Legal & General Group Plc lifted its stake in shares of Paratek Pharmaceuticals by 13.3% in the 2nd quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock valued at $144,000 after purchasing an additional 687 shares during the period. Quantbot Technologies LP acquired a new position in shares of Paratek Pharmaceuticals in the 2nd quarter valued at $172,000. Finally, Citigroup Inc. lifted its stake in shares of Paratek Pharmaceuticals by 19,470.0% in the 2nd quarter. Citigroup Inc. now owns 7,828 shares of the specialty pharmaceutical company’s stock valued at $189,000 after purchasing an additional 7,788 shares during the period. 82.00% of the stock is currently owned by institutional investors.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Earnings History and Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply